Activity Details

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

• Describe criteria for SMA diagnosis
• Describe how SMA diagnosis can be missed or delayed

Activity Description

This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.

Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.

Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.

Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.

Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.

J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

• Describe criteria for SMA diagnosis
• Describe how SMA diagnosis can be missed or delayed

Activity Description

This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.

Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.

Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.

Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.

Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.

J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Learning Objectives

Upon completion of the activity participants should be able to:

• Diagnose MS accurately and understand the importance of timely initiation of treatment
• Recognize early signs of disease progression and understand the importance of long-term surveillance
• Review current and emerging DMTs for the management of MS
• Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Patricia Melville, RN, MSN, NP-C, MSCN
Clinical Instructor
Department of Neurology
SUNY at Stony Brook
Stony Brook, New York

Method of Participation/How to Receive Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

• Patricia Melville, RN, MSN, NP-C, MSCN, has served as a consultant for Biogen, EMD Serono, Sanofi-Genzyme, Roche/Genentech, Novartis, and Celgene. She has also done contract research for Corrona LLC, Biogen, MedDay Pharmaceuticals, Novartis, Roche/Genentech, and Johnson & Johnson.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Learning Objectives

Upon completion of the activity participants should be able to:

• Diagnose MS accurately and understand the importance of timely initiation of treatment
• Recognize early signs of disease progression and understand the importance of long-term surveillance
• Review current and emerging DMTs for the management of MS
• Develop an effective treatment plan for the patient with MS to prevent progression of disease

Faculty

Patricia Melville, RN, MSN, NP-C, MSCN
Clinical Instructor
Department of Neurology
SUNY at Stony Brook
Stony Brook, New York

Method of Participation/How to Receive Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Accredited Provider

Target Audience

This activity was developed for neurologists, MS subspecialists, primary care clinicians, and other health care professionals involved in the treatment and management of patients with MS.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

• Patricia Melville, RN, MSN, NP-C, MSCN, has served as a consultant for Biogen, EMD Serono, Sanofi-Genzyme, Roche/Genentech, Novartis, and Celgene. She has also done contract research for Corrona LLC, Biogen, MedDay Pharmaceuticals, Novartis, Roche/Genentech, and Johnson & Johnson.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Genentech.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright Information

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission.

Privacy Policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

• Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
• Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
• Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
• Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
• Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

• Welcome and Session Overview
• Pathophysiology and Mechanism of Action Depicted in Mixed Reality
• Cases in Episodic Migraine and Episodic Cluster Headache
• Question and Answer Session
• Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

• Planner (Forefront Collaborative): Sydney Pate, MS
• Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

• Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
• Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
• Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
• Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
• Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
• Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

• Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
• Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
• Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
• Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
• Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

• Welcome and Session Overview
• Pathophysiology and Mechanism of Action Depicted in Mixed Reality
• Cases in Episodic Migraine and Episodic Cluster Headache
• Question and Answer Session
• Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

• Planner (Forefront Collaborative): Sydney Pate, MS
• Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

• Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
• Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
• Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
• Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
• Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
• Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neuromuscular specialists, pediatricians, and other health care professionals involved in the management of patients with limb-girdle muscular dystrophies (LGMD).

Learning Objectives

• Evaluate the genetic and molecular causes of the major subtypes of LGMD as well as the clinical implications for patients.
• Examine the heterogeneity in symptoms experienced by patients with LGMD and the implications for patient management.
• Assess appropriate tests and medical work-up to aid in the timely and accurate subtype diagnosis for patients with LGMD.

Activity Description

Limb girdle muscular dystrophies (LGMD) are a group of rare neuromuscular disorders characterized by weakness and wasting of the muscles in the shoulder and pelvic girdles. The severity, age of onset, and heterogeneity are determined by mutations in various genes. To date, there are no disease-modifying options for patients with LGMD; instead, management is based on multidisciplinary care to treat the symptoms and prevent further progression. As the science surrounding LGMD and its treatment continues to evolve, it is imperative that neurologists and other providers understand the mechanisms of disease, the difference in subtypes, and how to achieve accurate diagnosis. To address these topics, experts on LGMD will present a web-based educational activity featuring multidisciplinary perspectives.

Agenda

• Introduction
• Limb Girdle Molecular Dystrophies - Prevalence and Symptoms
• Genetic Causes of LGMD - Implications for Disease Heterogeneity and Diagnosis
• Achieving Accurate Subtype Diagnosis in LGMD - A Discussion of Best Practices
• Conclusion

Activity Chair

Matthew P. Wicklund, MD
Professor of Neurology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Consulting Fee: Sarepta
Contracted Research: Muscular Dystrophy Association
Ownership Interest: Myonexuss

Faculty

Nicholas Johnson, MD, MSCI
Vice Chair of Research
Associate Professor
Virginia Commonwealth University
Richmond, VA

Disclosure:
Intellectual Property/Patent Details: University of Rochester
Consulting Fee: AskBio, AveXis, Dyne, ML Bio Solutions, Sarepta, Triplett, Vertex
Contracted Research: AveXis, ML Bio Solutions, Sarepta, Vertex
Ownership Interest: ML Bio Solutions

Monkol Lek, PhD
Assistant Professor
Yale University School of Medicine
New Haven, CT

Disclosure:
No relevant financial relationships to disclose.

Katherine D. Mathews, MD
Professor, Departments of Pediatrics and Neurology
Vice Chair for Clinical Research, Department of Pediatrics
University of Iowa Carver College of Medicine
Iowa City, IA

Disclosure:
Consulting Fee (paid to institution): Asklepios, AveXis, Santhera, Sarepta
Contracted Research: Hoffmann-La Roche, Pfizer, PTC Therapeutics, Santhera, Sarepta, Wave

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

• Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

• Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sarepta Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neuromuscular specialists, pediatricians, and other health care professionals involved in the management of patients with limb-girdle muscular dystrophies (LGMD).

Learning Objectives

• Evaluate the genetic and molecular causes of the major subtypes of LGMD as well as the clinical implications for patients.
• Examine the heterogeneity in symptoms experienced by patients with LGMD and the implications for patient management.
• Assess appropriate tests and medical work-up to aid in the timely and accurate subtype diagnosis for patients with LGMD.

Activity Description

Limb girdle muscular dystrophies (LGMD) are a group of rare neuromuscular disorders characterized by weakness and wasting of the muscles in the shoulder and pelvic girdles. The severity, age of onset, and heterogeneity are determined by mutations in various genes. To date, there are no disease-modifying options for patients with LGMD; instead, management is based on multidisciplinary care to treat the symptoms and prevent further progression. As the science surrounding LGMD and its treatment continues to evolve, it is imperative that neurologists and other providers understand the mechanisms of disease, the difference in subtypes, and how to achieve accurate diagnosis. To address these topics, experts on LGMD will present a web-based educational activity featuring multidisciplinary perspectives.

Agenda

• Introduction
• Limb Girdle Molecular Dystrophies - Prevalence and Symptoms
• Genetic Causes of LGMD - Implications for Disease Heterogeneity and Diagnosis
• Achieving Accurate Subtype Diagnosis in LGMD - A Discussion of Best Practices
• Conclusion

Activity Chair

Matthew P. Wicklund, MD
Professor of Neurology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Consulting Fee: Sarepta
Contracted Research: Muscular Dystrophy Association
Ownership Interest: Myonexuss

Faculty

Nicholas Johnson, MD, MSCI
Vice Chair of Research
Associate Professor
Virginia Commonwealth University
Richmond, VA

Disclosure:
Intellectual Property/Patent Details: University of Rochester
Consulting Fee: AskBio, AveXis, Dyne, ML Bio Solutions, Sarepta, Triplett, Vertex
Contracted Research: AveXis, ML Bio Solutions, Sarepta, Vertex
Ownership Interest: ML Bio Solutions

Monkol Lek, PhD
Assistant Professor
Yale University School of Medicine
New Haven, CT

Disclosure:
No relevant financial relationships to disclose.

Katherine D. Mathews, MD
Professor, Departments of Pediatrics and Neurology
Vice Chair for Clinical Research, Department of Pediatrics
University of Iowa Carver College of Medicine
Iowa City, IA

Disclosure:
Consulting Fee (paid to institution): Asklepios, AveXis, Santhera, Sarepta
Contracted Research: Hoffmann-La Roche, Pfizer, PTC Therapeutics, Santhera, Sarepta, Wave

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

• Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

• Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sarepta Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com